tradingkey.logo
tradingkey.logo
Suchen

Telomir Pharmaceuticals Inc

TELO
Zur Watchlist hinzufügen
1.270USD
-0.030-2.31%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
42.97MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Telomir Pharmaceuticals Inc Unternehmen

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.

Telomir Pharmaceuticals Inc Informationen

BörsenkürzelTELO
Name des UnternehmensTelomir Pharmaceuticals Inc
IPO-datumFeb 09, 2024
CEOAminov (Erez)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 09
Addresse900 West Platt Street, Suite 200
StadtTAMPA
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl33606
Telefon18138642562
Websitehttps://telomirpharma.com/
BörsenkürzelTELO
IPO-datumFeb 09, 2024
CEOAminov (Erez)

Führungskräfte von Telomir Pharmaceuticals Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.73M
+83.85%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.73M
+83.85%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Telomir Pharmaceuticals Inc?

Die fünf größten Anteilseigner von Telomir Pharmaceuticals Inc sind: Mr. Erez Aminov

Wie viele Institutionen halten Anteile an Telomir Pharmaceuticals Inc (TELO)?

Mit Stand vom 2026Q1 halten 110 Institutionen Anteile an Telomir Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 3.42M, was 9.95% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 488600.00 gestiegen.